Why Corcept Therapeutics now faces a bigger execution test after Lifyorli’s ROSELLA success
Corcept Therapeutics’ Lifyorli showed strong survival benefit in ovarian cancer. Read what the ROSELLA data could change for clinicians and payers.
Zentalis Pharmaceuticals aligns DENALI and ASPENOVA trials with evolving ovarian cancer treatment landscape
Zentalis Pharmaceuticals advances azenosertib through DENALI and ASPENOVA. Read what this means for ovarian cancer strategy and approval risk.
Can SIM0505’s Fast Track designation reshape the development outlook for NextCure, Inc. in ovarian cancer?
Can SIM0505’s Fast Track win accelerate NextCure’s ovarian cancer strategy? Read the full PDN analysis on risks, ASCO data, and regulatory outlook.
Can Corcept’s Lifyorli become a real new standard in platinum-resistant ovarian cancer after FDA approval?
Corcept’s Lifyorli won FDA approval in platinum-resistant ovarian cancer. Read what the survival data could change for clinicians, rivals, and regulators.
How Persevere Therapeutics plans to reposition misetionamide in a crowded ovarian cancer pipeline
Persevere Therapeutics launches misetionamide trial in platinum-resistant ovarian cancer. Discover what this dual-pathway strategy could mean for treatment.
Merck strengthens its women’s oncology position with KEYNOTE-B96 overall survival results
KEYNOTE-B96 shows overall survival gains for pembrolizumab in platinum-resistant ovarian cancer. Find out why this trial could reshape treatment strategy.